China Innovative Drug Reimbursement Needs Major Revamp: Industry Group
A domestic pharma industry group says China’s reimbursement scheme for innovative drugs needs rewriting to encourage innovation. At issue are a fixed reimbursement ratio maintained in the national public insurance program, the cycle of drug price negotiations, and exemptions from negotiations for expanded indications.
You may also be interested in...
Frontier Biotechnologies is seeking to enroll roughly 1,200 hospitalized COVID patients in an international Phase II/III clinical trial to evaluate its bofutrelvir (FB2001) in competition with Gilead’s Veklury.
Plus deals involving Shionogi/ Grünenthal, CR Biopharma/ImmVira, Elevation Oncology/CSPC, Everest Medicines/TTY Biopharm and Dr. Reddy’s/Slayback
A preliminary analysis of Russian Phase III results for azvudine, China's first home-grown antiviral for COVID-19, shows it reached two primary endpoints, but a separate Chinese study produced mixed results.